{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:25:04Z","timestamp":1782145504155,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00474-2","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:10:21Z","timestamp":1740561021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS (HAPPINESS study): protocol and baseline data for an observational study"],"prefix":"10.1186","volume":"9","author":[{"given":"Shuhei","family":"Takeyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironari","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusho","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi M.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Hisada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuro","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Horita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the HAPPINESS study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/1744666x.2021.1825940","volume":"16","author":"M Kato","year":"2020","unstructured":"Kato M, Sugimoto A, Atsumi T. Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. Expert Rev Clin Immunol. 2020;16:993\u20131004. https:\/\/doi.org\/10.1080\/1744666x.2021.1825940.","journal-title":"Expert Rev Clin Immunol"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/mr\/roac102","volume":"33","author":"K Ninagawa","year":"2023","unstructured":"Ninagawa K, Kato M, Kikuchi Y, Sugimori H, Kono M, Fujieda Y, et al. Predicting the response to pulmonary vasodilator therapy in systemic sclerosis with pulmonary hypertension by using quantitative chest CT. Mod Rheumatol. 2023;33:758\u201367. https:\/\/doi.org\/10.1093\/mr\/roac102.","journal-title":"Mod Rheumatol"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/rheumatology\/kead485","volume":"00","author":"H Moriya","year":"2023","unstructured":"Moriya H, Kato M, Hisada R, Ninagawa K, Tada M, Sakiyama K, et al. The chest CT signs for pulmonary veno-occlusive disease correlate with pulmonary haemodynamics in systemic sclerosis. Rheumatology (Oxford). 2023;00:1\u20136. https:\/\/doi.org\/10.1093\/rheumatology\/kead485.","journal-title":"Rheumatology (Oxford)"},{"key":"474_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roae033","author":"N Tokushige","year":"2024","unstructured":"Tokushige N, Hayashi Y, Omura J, Jinnai T, Atsumi T. Patient characteristics, diagnostic testing, and initial treatment profiles of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) using a Japanese claims database. Mod Rheumatol. 2024. https:\/\/doi.org\/10.1093\/mr\/roae033.","journal-title":"Mod Rheumatol"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1378\/chest.130.1.182","volume":"130","author":"O Sanchez","year":"2006","unstructured":"Sanchez O, Sitbon O, Ja\u00efs X, Simonneau G, Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest. 2006;130:182\u20139. https:\/\/doi.org\/10.1378\/chest.130.1.182.","journal-title":"Chest"},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","volume":"179","author":"R Condliffe","year":"2009","unstructured":"Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151\u20137. https:\/\/doi.org\/10.1164\/rccm.200806-953OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.30541","volume":"63","author":"M Humbert","year":"2011","unstructured":"Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522\u201330. https:\/\/doi.org\/10.1002\/art.30541.","journal-title":"Arthritis Rheum"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3899\/jrheum.130400","volume":"40","author":"H Gladue","year":"2013","unstructured":"Gladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J Rheumatol. 2013;40:1706\u201311. https:\/\/doi.org\/10.3899\/jrheum.130400.","journal-title":"J Rheumatol"},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","volume":"73","author":"JG Coghlan","year":"2014","unstructured":"Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73:1340\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203301.","journal-title":"Ann Rheum Dis"},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. https:\/\/doi.org\/10.1183\/13993003.01913-2018.","journal-title":"Eur Respir J"},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/art.37838","volume":"65","author":"CJ Valerio","year":"2013","unstructured":"Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. Arthritis Rheum. 2013;65:1074\u201384. https:\/\/doi.org\/10.1002\/art.37838.","journal-title":"Arthritis Rheum"},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1136\/annrheumdis-2011-200546","volume":"71","author":"S Bae","year":"2012","unstructured":"Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012;71:1335\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200546.","journal-title":"Ann Rheum Dis"},{"key":"474_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1136\/annrheumdis-2019-216476","volume":"79","author":"P Xanthouli","year":"2020","unstructured":"Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020;79:370\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216476.","journal-title":"Ann Rheum Dis"},{"key":"474_CR15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.chest.2018.05.002","volume":"154","author":"KD Kolstad","year":"2018","unstructured":"Kolstad KD, Li S, Steen V, Chung L. Long-Term outcomes in systemic Sclerosis-Associated pulmonary arterial hypertension from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry (PHAROS). Chest. 2018;154:862\u201371. https:\/\/doi.org\/10.1016\/j.chest.2018.05.002.","journal-title":"Chest"},{"key":"474_CR16","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/art.33460","volume":"64","author":"G Kovacs","year":"2012","unstructured":"Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, et al. Pulmonary arterial hypertension therapy May be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis Rheum. 2012;64:1257\u201362. https:\/\/doi.org\/10.1002\/art.33460.","journal-title":"Arthritis Rheum"},{"key":"474_CR17","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: an American college of rheumatology\/european league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424.","journal-title":"Ann Rheum Dis"},{"key":"474_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","volume":"31","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, et al. 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol. 2021;31:29\u201333. https:\/\/doi.org\/10.1080\/14397595.2019.1709944.","journal-title":"Mod Rheumatol"},{"key":"474_CR19","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725. https:\/\/doi.org\/10.1002\/art.1780400928.","journal-title":"Arthritis Rheum"},{"key":"474_CR20","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677\u201386. https:\/\/doi.org\/10.1002\/art.34473.","journal-title":"Arthritis Rheum"},{"key":"474_CR21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/nejm197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344\u20137. https:\/\/doi.org\/10.1056\/nejm197502132920706.","journal-title":"N Engl J Med"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American college of rheumatology\/european league against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210571.","journal-title":"Ann Rheum Dis"},{"key":"474_CR23","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1183\/09031936.00127113","volume":"43","author":"J Yorke","year":"2014","unstructured":"Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension. Eur Respir J. 2014;43:1106\u201313. https:\/\/doi.org\/10.1183\/09031936.00127113.","journal-title":"Eur Respir J"},{"key":"474_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1253\/circrep.CR-20-0014","volume":"2","author":"R Takeyasu","year":"2020","unstructured":"Takeyasu R, Tamura Y, Abe K, Goda A, Satoh T, Suda R, et al. Psychometric validation of a Japanese version of the emPHasis-10 questionnaire, a Patient-Reported outcome measure for pulmonary Hypertension\u3000- multicenter study in Japan. Circ Rep. 2020;2:255\u20139. https:\/\/doi.org\/10.1253\/circrep.CR-20-0014.","journal-title":"Circ Rep"},{"key":"474_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jacc.2017.12.010","volume":"71","author":"VV McLaughlin","year":"2018","unstructured":"McLaughlin VV, Hoeper MM, Channick RN, Chin KM, Delcroix M, Gaine S, et al. Pulmonary arterial Hypertension-Related morbidity is prognostic for mortality. J Am Coll Cardiol. 2018;71:752\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.12.010.","journal-title":"J Am Coll Cardiol"},{"key":"474_CR26","doi-asserted-by":"publisher","first-page":"1900586","DOI":"10.1183\/13993003.00586-2019","volume":"54","author":"S Jaafar","year":"2019","unstructured":"Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, et al. Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. Eur Respir J. 2019;54:1900586. https:\/\/doi.org\/10.1183\/13993003.00586-2019.","journal-title":"Eur Respir J"},{"key":"474_CR27","doi-asserted-by":"crossref","unstructured":"Ninagawa K, Kato M, Ohira H, Tsuneta S, Iwano H, Kono M et al. The assessment of left heart disease in patients with systemic sclerosis and pulmonary hypertension. Clin Exp Rheumatol. 2021;39 Suppl 131:103\u2013\u200910.","DOI":"10.55563\/clinexprheumatol\/c1j9gb"},{"key":"474_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1183\/09031936.00106008","volume":"34","author":"MJ Overbeek","year":"2009","unstructured":"Overbeek MJ, Vonk MC, Boonstra A, Voskuyl AE, Vonk-Noordegraaf A, Smit EF, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy. Eur Respir J. 2009;34:371\u20139. https:\/\/doi.org\/10.1183\/09031936.00106008.","journal-title":"Eur Respir J"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00474-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T09:10:25Z","timestamp":1740561025000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00474-2","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Hokkaido University Hospital (approval number: 022\u20130109). It has been registered in the Japan Registry of Clinical Trials as jRCT1010220025 since November 7, 2022. All researchers involved in this study will comply with the Declaration of Helsinki and the Ethical Guidelines for Medical Research Involving Human Subjects. For retrospective observation (Fig.\u00a0A), participants have the opportunity to opt out of the study. Information regarding the study is disclosed on the webpage of each participating facility. For the prospective observation (Fig.\u00a0B\u00a0C), written informed consent was obtained from all patients before prospective study procedures were performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Study participants are informed that their anonymized data will be published in academic journals and provide the written consent form for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study will be conducted fairly by the principal researcher (and group) of this university and will be funded by Janssen Pharmaceutical K.K. Approval for conflicts of interest in this study has been obtained from the Conflict-of-Interest Committee of Hokkaido University Hospital, ensuring fairness. H Hanaoka has received speaking fees from Asahi-Kasei, Chugai, Astellas, and Eli Lilly. A Hashimoto has received speaking fees from Eisai, Janssen, Mochida Pharmaceutical, Nippon Shinyaku, Daiichi Sankyo Company. M Kuwana has received research grants from MBL, consultant\/speaking fees from Asahi-Kasei, AstraZeneca, Boehringer-Ingelheim, Chugai, GSK, Janssen, Kissei, MBL, Mochida, and Ono Pharmaceuticals. T Higuchi has received speaking fees or consulting fees from Chugai, Pfizer, Boehringer, Asahi Kasei, Gilead, Eli Lilly, Janssen, and RIBOMIC, and belongs to an endowment department that is supported with an unrestricted grant from Ayumi, Asahi Kasei, Taisho, Mochida, Chugai, and AbbVie. YM Ito is a member of Independent Data Monitoring Committee of Janssen Pharmaceutical K.K. R. Hisada has received speaking fees from AbbVie Inc., Asahi-Kasei Co., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd., Eisai Co. Ltd., Janssen Pharmaceutical K.K., Nippon Boehringer Ingelheim Co., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc. T Atsumi has received research grants from Astellas, Takeda, Mitsubishi Tanabe, Chugai, Daiichi-Sankyo, Otsuka, Pfizer, Alexion, Bayer, Otsuka, Chugai, Takeda, Eisai, Bristol-Myers Squibb, Daiichi Sankyo, Mitsubishi Tanabe, and Asahi Kasei; consultant fees from Ono, Sanofi, Daiichi Sankyo, and Pfizer; and speaking fees from Mitsubishi Tanabe, Chugai, Astellas, Takeda, Pfizer, Daiichi Sankyo, Bristol-Myers Squibb, and Eli Lilly. M Kato has received research grants from AbbVie, Actelion, GlaxoSmithKline, Janssen, Nippon Shinyaku, and Novartis, and speaking fees from Astellas, Boehringer, Eisai, Eli Lilly, Janssen, Mitsubishi Tanabe, and Pfizer. The other authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}